Co-trimoxazol induced hyperkalemia
- Conditions
- HyperkalemiaAntibiotic treatmentAdverse drug reaction
- Registration Number
- NL-OMON21992
- Lead Sponsor
- Canisius Wilhelmina Hospital, department of Clinical Pharmacy, Nijmegen, the Netherlands
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Admission date to the Canisius Wilhelmina hospital in the period of January 1st 2013 until December 31st 2015
- Receiving at least 1920mg intravenous co-trimoxazole per 24h for at least 48h or at least 2g intravenous ceftriaxone per 24h for at least 48h
Exclusion Criteria
- Age under 18 years at the day of start of antibiotic treatment
- Admission to the intensive care unit during the antibiotic treatment period
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We will compare the surges in serum potassium levels of both groups. We will compare these surges in serum potassium by measuring serum potassium before and after the start of antibiotic treatment.
- Secondary Outcome Measures
Name Time Method We will measure several secondary outcomes, including serum creatinin (before and after the start of antibiotic treatment), the incidence of hyperkalemia, co-factors that influence serum potassium, the amount of serum potassium measurements (before and after the initiation of antibiotic therapy, as a variable to measure medication safety), hyperkalemia-associated complications such as mortality and a possible dose-response effect on serum potassium in the co-trimoxazole group.